



## Revance to Participate in the Goldman Sachs 40th Annual Global Healthcare Conference

June 4, 2019

NEWARK, Calif.--(BUSINESS WIRE)--Jun. 4, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the company will participate in the Goldman Sachs 40th Annual Global Healthcare Conference in Rancho Palos Verdes, CA.

President and Chief Executive Officer, Dan Browne, is scheduled to present on Tuesday, June 11 at 3:20 p.m. PT.

Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at [www.revance.com](http://www.revance.com). The webcast replay will be available after the conclusion of the live presentation for approximately 30 days.

### About Revance Therapeutics, Inc.

Revance Therapeutics is a biotechnology company focused on developing transformative neuromodulators to address a broad spectrum of aesthetic and therapeutic conditions. Revance's lead product candidate, DaxibotulinumtoxinA for Injection (DAXI), utilizes a unique proprietary peptide excipient technology combined with highly purified botulinum toxin type A to produce a novel, long-acting neuromodulator set to enter a \$4.5 billion global market. In aesthetics, Revance successfully completed its Phase 3 program for DAXI in glabellar (frown) lines and is currently pursuing U.S. regulatory approval in 2020, while also running two separate Phase 2 studies in forehead lines and lateral canthal lines (crow's feet). In therapeutics, DAXI is being studied in three indications, including a Phase 3 trial in cervical dystonia, a Phase 2 trial in adult upper limb spasticity, and a Phase 2 trial in plantar fasciitis, with plans to also study migraine. Beyond DAXI, Revance also has begun development of a biosimilar to BOTOX®, which would compete in the existing short-acting neuromodulator marketplace. More information on Revance may be found at [www.revance.com](http://www.revance.com).

"Revance Therapeutics" and the Revance logo are registered trademarks of Revance Therapeutics, Inc.

BOTOX® is a registered trademark of Allergan, Inc.

Source: Revance Therapeutics, Inc.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20190604005530/en/>

Source: Revance Therapeutics, Inc.

### INVESTORS

Revance Therapeutics, Inc.:  
Jeanie Herbert, 714-325-3584  
[jherbert@revance.com](mailto:jherbert@revance.com)

or

Gilmartin Group, LLC.:  
Laurence Watts, 619-916-7620  
[laurence@gilmartinir.com](mailto:laurence@gilmartinir.com)

### MEDIA

General Media:

Y&R:

Jenifer Slaw  
347-971-0906  
[jenifer.slaw@YR.com](mailto:jenifer.slaw@YR.com)

or

Trade Media:

Nadine Tosk, 504-453-8344  
[nadinepr@gmail.com](mailto:nadinepr@gmail.com)